Gelesis

United States
Panora, Iowa, United States, 02420

Company profile

Gelesis company profile

Gelesis is a clinical stage biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients. Gelesis100, our lead product, is an orally- administered smart pill which is constructed of materials that are General Recognized as Safe (GRAS) by the Food and Drug Administration (FDA). Each Gelesis100 capsule contains thousands of hydrogel particles approximately the size of a grain of salt that expand to 100 times their dry weight. The pill is designed to act mechanically in the stomach and small intestine to increase satiety and decrease hunger, resulting in reduced caloric intake and weight loss. <a href="http://www.gelesis.com/">Gelesis</a> was founded in 2006 in Boston, Massachusetts

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$1M-$10M
Founded
2006-02-01, Month

Headquarters

Postal code
02420
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
12
Total equity funding
$202.2M
Last funding
Post IPO Debt / $100M / 2022-01-14
Last equity funding
Private Equity / $84M
Investors
9
Lead investors
4
Founders
2
Articles
53
Exited on
2020-08-28

Founders and investors

Founders

Eyal S. RonYishai Zohar

Lead investors

OrbiMedPureTech HealthQIC BioVenturesVitruvian Partners

Investors

Cormorant Asset ManagementInvescoOrbiMedSalicaVitruvian Partners